Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

Phase 4 Completed 20 enrolled Mayo Clinic National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The overall goal of this study was to determine the effect of exenatide on gastric emptying, satiety and satiation in obese participants. The hypothesis in this study was that exenatide retards gastric emptying in obese patients with baseline accelerated gastric emptying.

Timeline

Start: 2014-06
Primary completion: 2015-03
Completion: 2015-03

Outcome

Met primary endpoint

paper Exenatide delayed GE of solids (T1/2 [Δ] 86 min relative to placebo, P < 0.001) PMID 26542264 ↗

registry analysis (superiority or other test); Exenatide vs Placebo; p <.001; ANCOVA NCT02160990 ↗

Publications

Results Acosta A, Camilleri M, Burton D, O'Neill J, Eckert D, Carlson P, Zinsmeister AR. Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Physiol Rep. 2015 Nov;3(11):e12610. doi: 10.14814/phy2.12610.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	5 ug	Subcutaneous